Articles
-
2 months ago |
hemophilianewstoday.com | Marisa Wexler |Susie Strachan |Jennifer Lynne |Andrea Lobo
Ixinity (trenonacog alfa) can effectively prevent and control bleeds in young children with severe or moderately severe hemophilia B, according to data from a Phase 3/4 clinical trial. “This study showed that [Ixinity] was safe and effective as prophylaxis and for controlling bleeds in previously treated persons with hemophilia [younger than] 12 years,” researchers wrote.
-
2 months ago |
alsnewstoday.com | Margarida Maia |Dagmar Munn |Mary Chapman |Susie Strachan
Fifteen nonprofit organizations across the U.S. formed a new ALS group, ALS United, to better address the needs of people living with amyotrophic lateral sclerosis (ALS) and drive advances in research toward better treatment options or a cure. The groups said they plan to pool resources to support and advocate for patients and their families at the state and national levels, and to promote research efforts worldwide.
-
Nov 14, 2024 |
friedreichsataxianews.com | Marisa Wexler |Susie Strachan |Elizabeth Hamilton |Sean Baumstark
The relationship between Friedreich’s ataxia (FA) patients and their caregivers can be complex. To make it work for everyone involved, it’s important to practice open communication and empathy, and to ask for help whenever it’s needed. Those are the key takeaways from a new webinar, “Stronger Together: Patient and Caregiver Collaboration in FA,” which was presented Nov. 6 by Friedreich’s Ataxia Newsand its parent company, Bionews.
-
Nov 7, 2024 |
musculardystrophynews.com | Margarida Maia |Betty Vertin |Susie Strachan |Robin Stemple
Specific genetic mutations in Duchenne muscular dystrophy (DMD) influence how long patients retain the ability to walk, even when treated with corticosteroids, according to a study that highlights the importance of genetic testing in predicting disease progression.
-
Oct 15, 2024 |
smanewstoday.com | Susie Strachan |Mary Chapman |Kevin Schaefer
This definitely happened, especially with the treatment of the new drugs that came out for spinal muscular atrophy, right? There were so many options, and as drugs were getting approved, I spoke to my neurologist. I let them know about the new treatment. They told me that, you know, it had only been approved for children, that the options, you know, or the studies weren’t really there for adults, which I totally respected. I respect her opinion.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →